Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT04930887

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

Led by Stanford University · Updated on 2026-04-27

15

Participants Needed

1

Research Sites

382 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).

CONDITIONS

Official Title

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a chief complaint of craniofacial pain including migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, or paroxysmal hemicrania
  • Patients seen at Stanford Pain & ENT clinic
Not Eligible

You will not qualify if you...

  • Age under 18 or over 80 years
  • Pregnant women
  • Economically disadvantaged individuals unable to afford clinic visits or treatments
  • Individuals unable to provide informed consent
  • Allergy to bupivacaine
  • Unable or unwilling to participate or planning to participate in another clinical study during this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peter H Hwang

Stanford, California, United States, 94304

Actively Recruiting

Loading map...

Research Team

P

Peter Hwang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here